摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-氯-4(3H)-喹唑啉酮 | 60233-66-1

中文名称
5-氯-4(3H)-喹唑啉酮
中文别名
5-氯-3H-喹唑啉-4-酮
英文名称
5-chloroquinazolin-4(3H)-one
英文别名
5-chloroquinazoline-4(3H)-one;5-chloro-4-hydroxyquinazoline;5-Chloro-3H-quinazolin-4-one;5-chloro-3H-quinazolin-4-one
5-氯-4(3H)-喹唑啉酮化学式
CAS
60233-66-1
化学式
C8H5ClN2O
mdl
MFCD01569827
分子量
180.593
InChiKey
ZDPCOXNOQQRKCN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    210 °C
  • 沸点:
    353.6±44.0 °C(Predicted)
  • 密度:
    1.50±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    41.5
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:c2e2579a3b4e942033653b076952847f
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-Chloro-4-quinazolone
Synonyms: 5-Chloroquinazolin-4(3H)-one; 5-chloro-4-quinazolinone; 5-chloroquinazolin-4-ol

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5-Chloro-4-quinazolone
CAS number: 60233-66-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H5ClN2O
Molecular weight: 180.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-氯-4(3H)-喹唑啉酮三氯氧磷 作用下, 反应 2.0h, 生成 4,5-二氯喹唑啉
    参考文献:
    名称:
    发现含有喹唑啉基的苯甲酰胺衍生物作为具有体外和体内抗肿瘤活性的新型 HDAC1 抑制剂
    摘要:
    设计、合成了一系列含喹唑啉基的苯甲酰胺衍生物,并评估了其体外组蛋白脱乙酰酶 1 (HDAC1) 抑制活性。化合物11a在 HDAC1 酶抑制活性和针对选定的一组癌细胞类型(Hut78、K562、Hep3B 和 HCT116 细胞)的细胞抗增殖活性方面均超过了已知的 I 类选择性 HDAC 抑制剂 MS-275,且未观察到对人类正常细胞的影响细胞。特别是,与其他测试的 HDAC 同工型(HDAC2、HDAC6 和 HDAC8)相比,化合物11a对 HDAC1 的抑制作用具有可接受的安全性。此外,化合物11a表现出良好的口服药代动力学特性,并在体内A549肿瘤异种移植模型中显示出显着的抗肿瘤活性。
    DOI:
    10.1016/j.bioorg.2021.105407
  • 作为产物:
    描述:
    3-氯-2-甲基苯胺盐酸potassium permanganate 、 magnesium sulfate 作用下, 以 二氯甲烷 为溶剂, 反应 8.5h, 生成 5-氯-4(3H)-喹唑啉酮
    参考文献:
    名称:
    Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors
    摘要:
    The synthesis and biological activity of a series of novel 5-substituted-4-hydroxy-8-nitroquinazolines that may function as inhibitors of EGFR- and/or ErbB-2-related oncogenic signaling are described. These compounds were prepared by SNAr reaction of 5-chloro-4-hydroxy-8-nitroquinazo line with alkyl or aryl amines, or alkyl alcohol as nucleophiles. Although the enzyme assay showed a weak inhibition effect against both EGFR and ErbB-2 tyrosine kinases, the cell-based antitumor activity turned out promising. Compounds having 5-anilino substituent exhibit high potency with 5-(4-methoxy)anilino-4-hydroxy-8-nitroquinazoline (1h) being the best dual EGFR/ErbB-2 inhibitors, which effectively inhibited the growth of both EGFR (MDA-MB-468, IC50 < 0-01 mu M) and ErbB-2 (SK-BR-3, IC50 = 13 mu M) overexpressing human tumor cell lines in vitro. More interestingly, the variation of the substituent(s) at the 3- and/or 4-position of the 5-anilino portion was found to modulate the selectivity and potency dramatically. However, compounds having an alkylamino or alkyloxy group at the 5-position of 4-hydroxy-8-nitroquinazolines are essentially inactive. These results are consistent with molecular modeling observations. This study was the first attempt to identify new structural types of dual EGFR/ErbB-2-related signaling inhibitors by incorporation of the anilino group at the 5-position of 4-hydroxy-8-nitroquinazolines' core structure, providing promising new templates for further development of potent inhibitors targeting both EGFR and ErbB-2 tyrosine kinases. (c) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2005.05.045
点击查看最新优质反应信息

文献信息

  • Design, Synthesis, and Potency of Pyruvate Dehydrogenase Complex E1 Inhibitors against Cyanobacteria
    作者:Yuan Zhou、Jiangtao Feng、Hongwu He、Leifeng Hou、Wen Jiang、Dan Xie、Lingling Feng、Meng Cai、Hao Peng
    DOI:10.1021/acs.biochem.7b00636
    日期:2017.12.12
    designed and synthesized. A part of 10, 17, and 21 displayed potent inhibition of Escherichia coli pyruvate dehydrogenase complex E1 (E. coli PDHc-E1) (IC50 = 2.12–18.06 μM) and good inhibition of Synechocystis sp. PCC 6803 (EC50 = 0.7–7.1 μM) and Microcystis sp. FACH 905 (EC50 = 3.7–7.6 μM). The algaecidal activity of these compounds positively correlated with their inhibition of E. coli PDHc-E1. In particular
    需要安全有效的除藻剂来控制具有农业和环境意义的藻类。四个系列(6,10,17,和21 29新的4-氨基嘧啶衍生物)的合理设计和合成。的一部分10,17,和21中显示的有效抑制大肠杆菌丙酮酸脱氢酶复合物E1(大肠杆菌PDHC-E1)(IC 50 = 2.12-18.06μM)和抑制良好的集胞藻属。PCC 6803(EC 50 = 0.7–7.1μM)和微囊藻。FACH 905(EC 50= 3.7–7.6μM)。这些化合物的杀藻活性与它们对大肠杆菌PDHc-E1的抑制作用正相关。特别是21l和10b表现出对PCC 6803的强效杀藻活性(分别为EC 50 = 0.7和0.8μM),其值是硫酸铜(EC 50 = 1.8μM)的2倍,并且表现最佳抑制蓝细菌PDHc-E1(IC 50分别为5.10和6.06μM )。17h和21e是大肠杆菌的最佳抑制剂通过分子对接,定点诱变和酶促测定研究了PDHc
  • Substituted Isoquinolines and Quinazolines as Potential Antiinflammatory Agents. Synthesis and Biological Evaluation of Inhibitors of Tumor Necrosis Factor α
    作者:Qi Chao、Lynn Deng、Hsiencheng Shih、Lorenzo M. Leoni、Davide Genini、Dennis A. Carson、Howard B. Cottam
    DOI:10.1021/jm9805900
    日期:1999.9.1
    mice. Thus, compounds such as 75, which can effectively inhibit proinflammatory cytokines such as TNFalpha in clinically relevant animal models of inflammation and fibrosis, may have potential as new antiinflammatory agents. Finally, a quinazoline derivative suitable to serve as a photoaffinity radiolabeled compound was prepared to help identify the putative cellular target(s) for these TNFalpha inhibitors
    制备了一系列异喹啉-1-酮和喹唑啉-4-酮及其相关衍生物,并评估了它们抑制细菌脂多糖(LPS)刺激的人外周血单核细胞中肿瘤坏死因子α(TNFα)产生的能力。为了优化TNFα抑制活性,制备了一系列同源的N-链烷酸酯。还进行了几次亲电和亲核取代。发现在异喹啉和喹唑啉系列中,四个碳的链烷酸酯对于活性是最佳的。异喹啉环上的环取代基(如氟,溴,硝基,乙酰基和氨基甲基)导致活性显着下降。同样,喹唑啉环上的相似基团也降低了抑制活性。然而,6和7-氨基喹唑啉衍生物75和76是有效的抑制剂,在TNFalpha体外测定中,每种IC的IC(50)值约为5 microM。然后将小鼠体内肺炎症模型用于评估在初步体外试验中鉴定出的有希望的候选化合物。在该吸入模型中选择了化合物75进行进一步研究,发现化合物75可将LPS处理小鼠的支气管肺泡灌洗液中的TNFα水平降低至对照小鼠的TNFα水平的约50%。因此,在临床相关的
  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    申请人:——
    公开号:US20020119975A1
    公开(公告)日:2002-08-29
    Disclosed are novel compounds of formula (I): 1 wherein Ar 1 , X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.
    公开了式(I)的新颖化合物:1,其中Ar1、X、Y、P、Q和Het在本说明书中有所定义,这些化合物作为某些蛋白酪氨酸激酶的抑制剂具有用途,因此可用于治疗由细胞异常增殖引起的疾病,包括自身免疫疾病、慢性炎症疾病、过敏性疾病、移植排斥和癌症,以及由脑缺血引起的状况,如中风。还公开了包含这些化合物的药物组合物、制备这些化合物的工艺以及在这些工艺中有用的新颖中间体化合物。
  • 一种喹唑啉酮类化合物及其制备方法
    申请人:河北科技大学
    公开号:CN111116552B
    公开(公告)日:2022-10-11
    本发明涉及化学合成技术领域,具体公开一种喹唑啉酮类化合物及其制备方法。所述喹唑啉酮类化合物,其结构如式(Ⅰ)所示,其中,R1为氢、卤素、甲氧基、甲基、硝基或三氟甲基;R2为或R3为氢、卤素、甲氧基或甲基。本发明提供了一种新型结构的喹唑啉酮类化合物,丰富了喹唑啉酮类化合物的种类,为发展抗炎、抗肿瘤、抗惊厥或抗真菌药物提供了一种新化合物,对于研究该类化合物的活性以及扩大该类化合物在医学领域和工业生产上的应用具有十分重要的意义,为研究具有独特生理活性的新型药物提供了基础。
  • Scandium-catalyzed Michael addition of quinazolinones and vinylazaarenes
    作者:Zhiguang Zhang、Siwei Dai、Ling Li、Chenyu Jia、Yong Zhang、Hao Li
    DOI:10.1016/j.tetlet.2020.151926
    日期:2020.6
    We described a novel scandium-catalyzed selective Michael addition of quinazolinones and vinylazaarenes. The protocol proceeds smoothly to give diverse quinazolinone derivatives in moderate to excellent yields. The high practicality of this protocol was proved by excellent chemo selectivity and broad substrate and functional group compatibility.
    我们描述了一种新颖的scan催化的喹唑啉酮和乙烯基氮杂芳烃的选择性迈克尔加成反应。该方案顺利进行,以中等至极好的收率得到了各种喹唑啉酮衍生物。该方案的高度实用性由出色的化学选择性以及广泛的底物和官能团相容性证明。
查看更多